Ireland
--:--IST
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esophageal Adenocarcinoma
Clinical trial register · United States · industry-sponsored

Esophageal Adenocarcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9107 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Oct 2026, 03:16 UTC
9107
Studies in scope
industry-sponsored, all four open statuses
4948
Recruiting now
open to new participants
2191
Lead sponsors
across recruiting studies
Top states
California 7 Florida 6 Colorado 6 Massachusetts 5 New York 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Esophageal Adenocarcinoma trials in the USA

12 of 9107 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
NCT07546812HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Gilead Sciences
Phase 2
120
Massachusetts, New York
2026-08-07
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York
2026-05-14
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Massachusetts, Ohio, Tennessee
2026-04-13
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
AbbVie
Phase 2
185
California, Florida, Georgia, Mississippi, North Carolina, Texas
2024-12-13
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim
Phase 1/2
768
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
Taiho Oncology, Inc.
Phase 2
53
California, Colorado, Florida, Michigan, New Jersey, New York, Ohio, Pennsylvania
2023-07-13
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
392
Florida, Minnesota, New York
2023-07-11
Recruiting
Lucid Registry Study
NCT05965999Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Lucid Diagnostics, Inc.
Observational
8,000
California
2023-04-11
Active, closed
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Arizona, Colorado, District of Columbia, Missouri, New Mexico, North Carolina, Ohio, Washington
2020-09-15
Active, closed
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Lucid Diagnostics, Inc.
Not applicable
784
Colorado, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan
2020-06-18
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/esophageal-adenocarcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,107 studies in total at the last sync on 02 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Esophageal Adenocarcinoma.

How many Esophageal Adenocarcinoma trials are recruiting in the US?

7 of the 12 studies on this page are recruiting new participants as of the 02 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esophageal Adenocarcinoma), 12 studies
PhaseStudiesRecruitingShare
Phase 24133.3%
Phase 13225%
Phase 1/22216.7%
Not applicable108.3%
Observational118.3%
Phase 2/3118.3%

Most active sponsors

Lead sponsors with the most studies (Esophageal Adenocarcinoma)
Lead sponsorStudiesRecruiting
Lucid Diagnostics, Inc.21
AbbVie10
AstraZeneca11
Boehringer Ingelheim11
Dispatch Biotherapeutics11
Gilead Sciences11
Normunity AccelCo, Inc.11
Pfizer11
Seagen, a wholly owned subsidiary of Pfizer10
SystImmune Inc.10

Top states

Top states (Esophageal Adenocarcinoma), by number of studies with a site there
StateStudies
California7
Colorado6
Florida6
Massachusetts5
Michigan4
New Jersey4
New York4
Ohio4
Connecticut3
District of Columbia3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.